China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm Health Sky Pharmaceutical. The collaboration aims to leverage their respective technology and resource advantages to jointly pursue new drug research and development, pre-clinical and clinical studies, and program incubation.
Partnership Details
HitGen brings to the table its advanced technologies, including DNA encoded library (DEL) technology, drug design technology based on molecular fragment and three-dimensional structure information (FBDD/SBDD), nucleic acid new drug development related technology (STO), and targeted protein degradation related technology (TPD). Health Sky, on the other hand, offers professional pre-clinical and clinical study services for top-tier pharmaceutical companies.
Financial Terms
No financial details were disclosed regarding the partnership.-Fineline Info & Tech
